These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25102754)

  • 1. [Analysis of the effect of antihypertensive drugs on left ventricular hypertrophy regression].
    Koziolova NA; Shatunova IM
    Kardiologiia; 2014; 54(3):82-91. PubMed ID: 25102754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of Antihypertensive Drugs on Regression of Left Ventricular Hypertrophy].
    Koziolova NA; Shatunova IM
    Kardiologiia; 2015; 55(6):88-97. PubMed ID: 26625525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antihypertensive agents on the left ventricle: clinical implications.
    Díez J; González A; López B; Ravassa S; Fortuño MA
    Am J Cardiovasc Drugs; 2001; 1(4):263-79. PubMed ID: 14728026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.
    Klingbeil AU; Schneider M; Martus P; Messerli FH; Schmieder RE
    Am J Med; 2003 Jul; 115(1):41-6. PubMed ID: 12867233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies.
    Fagard RH; Celis H; Thijs L; Wouters S
    Hypertension; 2009 Nov; 54(5):1084-91. PubMed ID: 19770405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats.
    Mizuno K; Niimura S; Katoh K; Fukuchi S
    Life Sci; 1994; 54(25):1987-94. PubMed ID: 8201847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A; Suzuki Y; Saruta T
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
    Schmieder RE; Martus P; Klingbeil A
    JAMA; 1996 May; 275(19):1507-13. PubMed ID: 8622227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure is normal, but is the heart?
    Çelik SF; Karakurt C; Tabel Y; Elmas T; Yoloğlu S
    Pediatr Nephrol; 2018 Sep; 33(9):1585-1591. PubMed ID: 29766272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antihypertensive treatment and left ventricular hypertrophy].
    Agabiti-Rosei E; Muiesan ML; Rizzoni D
    Ann Ital Med Int; 1993 Oct; 8 Suppl():97S-103S. PubMed ID: 8117529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study.
    Rakić D; Rumboldt Z; Bagatin J; Polić S
    Croat Med J; 2002 Dec; 43(6):672-9. PubMed ID: 12476475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of left ventricular hypertrophy in human hypertension.
    Kahan T
    J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996).
    Schmieder RE; Schlaich MP; Klingbeil AU; Martus P
    Nephrol Dial Transplant; 1998 Mar; 13(3):564-9. PubMed ID: 9550628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive drugs and the heart.
    Diamond JA; Phillips RA
    Curr Cardiol Rep; 2004 Nov; 6(6):409-15. PubMed ID: 15485599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study.
    Ripley DP; Negrou K; Oliver JJ; Worthy G; Struthers AD; Plein S; Greenwood JP
    Clin Exp Hypertens; 2015; 37(4):308-16. PubMed ID: 25271354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Gottdiener JS
    Circulation; 1999 Aug; 100(6):685-6. PubMed ID: 10490345
    [No Abstract]   [Full Text] [Related]  

  • 18. Left ventricular hypertrophy and angiotensin II antagonists.
    Dahlöf B
    Am J Hypertens; 2001 Feb; 14(2):174-82. PubMed ID: 11243310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real role of β-blockers in regression of left ventricular mass in hypertension patients: Bayesian network meta-analysis.
    Xing F; Chen J; Zhao B; Jiang J; Tang A; Chen Y
    Medicine (Baltimore); 2017 Mar; 96(10):e6290. PubMed ID: 28272254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.